Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'- O -Glucuronide Formation as a Selective UGT2B4 Probe Reaction.

Autor: Lapham K; Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut kimberly.lapham@pfizer.com., Ferguson N; Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut., Niosi M; Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut., Goosen TC; Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Groton, Connecticut.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2024 Sep 16; Vol. 52 (10), pp. 1083-1093. Date of Electronic Publication: 2024 Sep 16.

Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.

Autor: Callegari E; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA., Tse S; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA., Doran AC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA., Goosen TC; Medicine Design - Pharmacokinetics, Dynamics, and Metabolism, Pfizer Worldwide Research and Development, Pfizer Inc., Groton, CT, USA., Shaik N; Clinical Pharmacology and Bioanalytics, Pfizer Inc., La Jolla, CA, USA.

Publikováno v: Journal of clinical pharmacology [J Clin Pharmacol] 2024 Jan; Vol. 64 (1), pp. 80-93. Date of Electronic Publication: 2023 Oct 18.

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.

Autor: Bauman JN; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Doran AC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., King-Ahmad A; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Sharma R; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Walker GS; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Lin J; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Lin TH; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Telliez JB; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Tripathy S; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Goosen TC; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Banfield C; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Malhotra BK; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.)., Dowty ME; Medicine Design (M.E.D), Inflammation and Immunology (T.H.L., J.-B.T.), and Clinical Pharmacology (C.B.), Pfizer Inc., Cambridge, Massachusetts; Medicine Design (J.N.B., A.C.D., A.K.-A., R.S., G.S.W., J.L., T.C.G.) and Clinical Pharmacology (S.T.), Pfizer Inc., Groton, Connecticut; and Clinical Pharmacology, Pfizer Inc., New York, New York (B.K.M.) martin.dowty@pfizer.com.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Aug; Vol. 50 (8), pp. 1106-1118. Date of Electronic Publication: 2022 Jun 14.

Defining the Selectivity of Chemical Inhibitors Used for Cytochrome P450 Reaction Phenotyping: Overcoming Selectivity Limitations with a Six-Parameter Inhibition Curve-Fitting Approach.

Autor: Doran AC; Medicine Design - ADME Sciences, Pfizer, United States angela.c.doran@pfizer.com., Burchett W; Pfizer Inc., United States., Landers C; Pfizer Inc., United States., Gualtieri GM; Pfizer Inc., United States., Balesano A; Pfizer Inc., United States., Eng H; Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, United States., Dantonio AL; Pfizer, United States., Goosen TC; Pharmacokinetics, Dynamics & Metabolism, Pfizer, Inc, United States., Obach RS; Groton Laboratories, Pfizer Inc., United States.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Jul 01. Date of Electronic Publication: 2022 Jul 01.

Physiologically-Based Pharmacokinetic Modeling of the Drug-Drug Interaction of the UGT Substrate Ertugliflozin Following Co-Administration with the UGT Inhibitor Mefenamic Acid.

Autor: Callegari E; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA., Lin J; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA., Tse S; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA., Goosen TC; Department of Medicine Design-Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA., Sahasrabudhe V; Department of Clinical Pharmacology, Pfizer Global Research and Development, Pfizer Inc., Groton, Connecticut, USA.

Publikováno v: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Feb; Vol. 10 (2), pp. 127-136. Date of Electronic Publication: 2020 Dec 30.